CompletedPhase 2NCT04535609

An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients

Studying Mitochondrial myopathy

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Reneo Pharma Ltd
Principal Investigator
Amel Karaa, MD
Massachusetts General Hospital (MGH)
Intervention
Mavodelpar(drug)
Enrollment
213 target
Eligibility
18 years · All sexes
Timeline
20212023

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04535609 on ClinicalTrials.gov

Other trials for Mitochondrial myopathy

Additional recruiting or active studies for the same condition.

See all trials for Mitochondrial myopathy

← Back to all trials